VolitionRx Achieves Technical Milestone with Finger-Prick Test for Sepsis Detection

VolitionRx Limited (NYSE American: VNRX) announced a technical milestone in the detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples, supporting the potential for early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.

The company noted that the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. Volition emphasized that this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.

Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Early detection and treatment are critical to improving outcomes, yet current diagnostic methods often rely on central laboratory testing, which can delay results. Volition's finger-prick test aims to address this gap by providing a simple, rapid test that can be used at the bedside or in remote settings.

For more details, the full press release is available at https://ibn.fm/ioEmu.

Volition is a multi-national epigenetics company focused on developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

This milestone represents a significant step forward in Volition's mission to save lives and improve outcomes for people with life-altering diseases through earlier detection and monitoring. By enabling point-of-care testing, the company hopes to reduce the time to diagnosis and treatment initiation for sepsis patients, potentially improving survival rates and reducing healthcare costs.